Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants
申请人:7 Hills Interests LLC
公开号:US10342866B2
公开(公告)日:2019-07-09
Small molecule integrin ligand mimetics facilitate integrin-ligand interactions, which may be used to prepare vaccines, adoptive cell therapies, immunotherapies for cancer, and a variety of other conditions. As integrin mediated cell-cell interactions are critical to antigen presentation and effector cell killing, increasing the efficiency of integrin receptor-ligand interactions will stabilize the immune synapse and improve effector functions. Compositions and methods including the mimetics enhance: (1) the priming of vaccines (including, but not limited to, cancer vaccines); (2) cytolytic activity of adoptive cell therapies (including, but not limited to γδT-cells, CTLs, NK, iNKT); (3) immunotherapies (including, but not limited to, negative checkpoint blockage strategies such as anti-CTLA-4 and anti-PD-1); and (4) biologic therapies (including, but not limited, to trastuzumab and rituxamab), whereby the mechanism-of-action includes antibody dependent cellular cytotoxicity (ADCC).
小分子整合素配体模拟物能促进整合素与配体之间的相互作用,可用于制备疫苗、采用性细胞疗法、癌症免疫疗法以及其他多种治疗方法。由于整合素介导的细胞-细胞相互作用对于抗原递呈和效应细胞杀伤至关重要,因此提高整合素受体-配体相互作用的效率将稳定免疫突触并改善效应功能。包括模拟物在内的组合物和方法可提高(1) 疫苗(包括但不限于癌症疫苗)的启动;(2) 接种细胞疗法(包括但不限于γδT 细胞、CTL、NK、iNKT)的细胞溶解活性;(3) 免疫疗法(包括但不限于阴性检查点阻断策略,如抗 CTLA-4 和抗 PD-1);以及 (4) 生物疗法(包括但不限于曲妥珠单抗和利妥昔单抗),其作用机制包括抗体依赖性细胞毒性(ADCC)。